JNJJOHNSON & JOHNSON

NYSE jnj.com


$ 145.55 $ 0.09 (0.06 %)    

Friday, 14-Jun-2024 15:59:58 EDT
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 145.54
$ 145.16
$ 0.00 x 0
$ 0.00 x 0
$ 144.49 - $ 145.82
$ 141.57 - $ 170.63
4,075,342
na
353.68B
$ 0.48
$ 9.19
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-16-2024 12-31-2023 10-K
3 10-27-2023 10-01-2023 10-Q
4 10-27-2023 10-01-2023 10-Q
5 07-31-2023 07-02-2023 10-Q
6 04-28-2023 04-02-2023 10-Q
7 02-16-2023 01-01-2023 10-K
8 10-27-2022 10-02-2022 10-Q
9 07-29-2022 07-03-2022 10-Q
10 04-29-2022 04-03-2022 10-Q
11 02-17-2022 01-02-2022 10-K
12 10-29-2021 10-03-2021 10-Q
13 07-29-2021 07-04-2021 10-Q
14 04-30-2021 04-04-2021 10-Q
15 02-22-2021 01-03-2021 10-K
16 10-23-2020 09-27-2020 10-Q
17 07-24-2020 06-28-2020 10-Q
18 04-29-2020 03-29-2020 10-Q
19 02-18-2020 12-29-2019 10-K
20 10-28-2019 09-29-2019 10-Q
21 07-29-2019 06-30-2019 10-Q
22 05-01-2019 03-31-2019 10-Q
23 02-20-2019 12-30-2018 10-K
24 10-31-2018 09-30-2018 10-Q
25 08-02-2018 07-01-2018 10-Q
26 05-01-2018 04-01-2018 10-Q
27 02-21-2018 12-31-2017 10-K
28 11-02-2017 10-01-2017 10-Q
29 08-03-2017 07-02-2017 10-Q
30 05-08-2017 04-02-2017 10-Q
31 02-27-2017 01-01-2017 10-K
32 11-04-2016 10-02-2016 10-Q
33 08-04-2016 07-03-2016 10-Q
34 05-10-2016 04-03-2016 10-Q
35 02-24-2016 01-03-2016 10-K
36 10-30-2015 09-27-2015 10-Q
37 07-31-2015 06-28-2015 10-Q
38 05-01-2015 03-29-2015 10-Q
39 02-24-2015 12-28-2014 10-K
40 10-30-2014 09-28-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jj-reports-updated-phase-2-captivate-study-results-show-sustained-clinical-benefit-of-fixed-duration-imbruvica-plus-venetoclax

- Reuters

Core News & Articles

- Reuters

 johnson--johnson-to-pay-700m-to-settle-multi-state-talc-investigation

Although the settlement has been reached, Johnson & Johnson still faces a substantial number of talc-related lawsuits.

 johnson--johnson-reaches-700m-settlement-with-most-us-states-for-alleged-deceptive-marketing-of-talc-containing-products-massachusetts-attorney-general-says

- Reuters Citing Court Documents 

 new-york-attorney-general-files-lawsuit-against-johnson--johnson

- Reuters Citing Court Documents 

Core News & Articles

- Reuters

 abbvies-arthritis-drug-humira-retains-market-dominance-despite-biosimilar-competition-challenges-biosimilar-industry-viability

Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the b...

 johnson--johnson-medtechs-depuy-synthes-receives-fda-clearance-for-velys-robotic-assisted-solution-in-unicompartmental-knee-arthroplasty-uka

https://www.jnj.com/media-center/press-releases/depuy-synthes-receives-510k-fda-clearance-of-the-velys-robotic-assisted-solutio...

Core News & Articles

- Bloomberg

Core News & Articles

- Bloomberg

Core News & Articles

- Reuters

 johnson--johnson-submits-supplemental-nda-to-us-fda-seeking-expanded-pediatric-indication-for-hiv-1-therapy-prezcobix

- Reuters

 rbc-capital-reiterates-outperform-on-johnson--johnson-maintains-175-price-target

RBC Capital analyst Shagun Singh reiterates Johnson & Johnson (NYSE:JNJ) with a Outperform and maintains $175 price target.

 johnson--johnson-ordered-to-pay-260m-in-latest-talc-trial

The ruling comes as J&J continues to pursue a proposed $6.48 billion settlement of most talc-related lawsuits through a pre...

Core News & Articles

73 percent reduction in risk of disease progression or death seen with CARVYKTI® in the CARTITUDE-4 study in a subset of patien...